L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 557.2 ILS 1.62% Market Closed
Market Cap: 440.6m ILS

Operating Margin
Lineage Cell Therapeutics Inc

-186.9%
Current
-262%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-186.9%
=
Operating Profit
-20.4m
/
Revenue
10.9m

Operating Margin Across Competitors

No Stocks Found

Lineage Cell Therapeutics Inc
Glance View

Market Cap
440.6m ILS
Industry
Biotechnology

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The firm is engaged in developing cell therapies for unmet medical needs. The company is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The firm has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

LCTX Intrinsic Value
511.68 ILS
Overvaluation 8%
Intrinsic Value
Price
L
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-186.9%
=
Operating Profit
-20.4m
/
Revenue
10.9m
What is the Operating Margin of Lineage Cell Therapeutics Inc?

Based on Lineage Cell Therapeutics Inc's most recent financial statements, the company has Operating Margin of -186.9%.

Back to Top